RT Journal第SR电子T1轨迹和残留效果的死亡率受损肺活量测量仪：鹿特丹研究JF欧洲呼吸杂志Jo EUR Respir J FD欧洲呼吸学会SP 1901217 Do 10.1183 / 13993003.01217-2019 VO 55是1 A1 Wijnant，Sara Renata Alex A1 de188bet官网地址roos，ofmely a1 kavousi，maryam a1 stricker，布鲁诺·乌戈A1 Terzikhan，Natalie A1 Lahousse，谎言A1 Brusselle，Guy G. Yr 2020 UL //www.qdcxjkg.com/content/55/1/1901217.abstract ab保留比例受损肺活量测定法（棱镜）是异质条件，但其过程和疾病的进展仍然待阐明。我们的旨在探讨普遍存在的普遍存在，轨迹和预后。在鹿特丹研究（基于人口的前瞻性队列）中，我们检查了正常血液测定法的患病率，轨迹和预后（对照;强制呼气量在1 S（FEV1）/强制生命能力（FVC）≥0.7，FEV1≥80％），棱镜（FEV1 /FVC≥0.7，FEV1 <80％）和慢性阻塞性肺病（COPD）（FEV1 / FVC <0.7）在两项研究访问中。危险比率为95％的死亡率置信区间（直到2018年12月30日）调整为年龄，性别，体重指数，目前的吸烟和包装 - 多年。5487个受试者（年龄69.1±8.9岁; 7.1％棱镜），16034.5岁后重新审查。重新检查的棱镜受试者，15.7％转型至正常肺活量测定法，49.4％至COPD。中位肺功能下降在棱镜的主题中最高（FEV1 -92.8 ml·1年级 - 1，四分位数范围（IQR）-131.9--65.8毫升·年 - 1; FVC -93.3 ML·年1，IQR -159.8- −49.1 mL·year−1), but similar in persistent PRISm (FEV1 −30.2 mL·year−1, IQR −67.9– −7.5 mL·year−1; FVC −20.1 mL·year−1, IQR −47.7–21.7 mL·year−1) and persistent controls (FEV1 −39.6 mL·year−1, IQR −64.3–−12.7 mL·year−1; FVC −20.0 mL·year−1, IQR −55.4–18.8 mL·year−1). Of 5459 subjects with informed consent for follow-up, 692 (12.7%) died during 9.3 years (maximum) follow-up: 10.3% of controls, 18.7% of PRISm subjects and 20.8% of COPD subjects. Relative to controls, subjects with PRISm and COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2–4 had increased all-cause mortality (PRISm: HR 1.6, 95% CI 1.2–2.0; COPD GOLD 2–4: HR 1.7, 95% CI 1.4–2.1) and cardiovascular mortality (PRISm: HR 2.8, 95% CI 1.5–5.1; COPD 2–4: HR 2.1, 95% CI 1.2–3.6). Mortality within <1 year was highest in PRISm, with patients often having cardiovascular comorbidities (heart failure or coronary heart disease; 70.0%).PRISm is associated with increased mortality and this population encompasses at least three distinct subsets: one that develops COPD during follow-up, a second with high cardiovascular burden and early mortality, and a third with persistent PRISm and normal age-related lung function decline.Preserved ratio impaired spirometry, previously called restrictive spirometry, is a condition associated with increased mortality that encompasses distinct clinical subsets http://bit.ly/2ncclac